Daily Cosmetic Research Analysis
Three impactful studies span cosmetic safety, surgical cosmesis, and anti-scarring therapeutics. A Korean exposure assessment quantifies population-specific dermal doses of parabens and antimicrobials from cosmetics/personal care products, identifying high-contributing product categories. A split-scar comparative study shows tissue adhesive performs as well as sutures for trunk/extremity closures with fewer track marks, and a preclinical study identifies cepharanthine as an anti-fibrotic candida
Summary
Three impactful studies span cosmetic safety, surgical cosmesis, and anti-scarring therapeutics. A Korean exposure assessment quantifies population-specific dermal doses of parabens and antimicrobials from cosmetics/personal care products, identifying high-contributing product categories. A split-scar comparative study shows tissue adhesive performs as well as sutures for trunk/extremity closures with fewer track marks, and a preclinical study identifies cepharanthine as an anti-fibrotic candidate that inhibits TGF-β/SMAD signaling to prevent hypertrophic scars.
Research Themes
- Cosmetic and personal care product chemical exposure and risk assessment
- Aesthetic outcomes in surgical wound closure
- Anti-scarring therapeutics and fibrosis signaling
Selected Articles
1. Comparison of 5-0 Polypropylene Suture and N-Butyl/2-Octyl Cyanoacrylate for Closure of Surgical Wounds on the Trunk and Extremities: A Split Scar Study.
In a split-scar comparison of 58 trunk/extremity wounds, cyanoacrylate tissue adhesive achieved overall cosmetic outcomes comparable to 5-0 polypropylene sutures, with fewer track marks in sutured halves and superior performance of adhesive on the chest. Blinded one-year assessments support adhesive as a viable option beyond the head/neck.
Impact: This study fills a key evidence gap for trunk and extremity closures, using a within-patient split-scar design and blinded assessment to show non-inferiority of tissue adhesive with context-specific advantages. It can directly inform wound-closure choices to optimize cosmetic outcomes and efficiency.
Clinical Implications: For trunk/chest closures, cyanoacrylate adhesive can be considered as a first-line option to reduce track marks and avoid suture removal while maintaining cosmetic outcomes. Surgeons should individualize by anatomical site, with adhesives favored on the chest and equivalence on arm/back.
Key Findings
- Mean SCAR scores at 1 year did not differ between 5-0 polypropylene suture and N-butyl/2-octyl cyanoacrylate (p=0.78).
- Sutured wounds had more track marks than adhesive-closed wounds (p=0.04).
- Adhesive performed significantly better on the chest than sutures (p=0.04), with no differences on the arm or back.
Methodological Strengths
- Within-patient split-scar design minimizes inter-individual confounding.
- Blinded assessment at 1 year using a validated SCAR scale by two Mohs surgeons.
Limitations
- Moderate sample size and single adhesive formulation; generalizability to other adhesives/suture types is uncertain.
- Study restricted to trunk and extremities; results may not extrapolate to other anatomical regions or high-tension closures.
Future Directions: Prospective randomized trials stratified by anatomical site and tension, cost-effectiveness analyses, and patient-reported outcomes could refine closure algorithms for different body regions.
BACKGROUND: The use of tissue adhesive for closures on the head and neck is well documented; however, there is a lack of data for scar outcomes on the trunk and extremities. OBJECTIVE: The objective of this study was to assess differences in scar cosmetic outcomes between 5-0 polypropylene suture (5-PS) and N-butyl/2-octyl cyanoacrylate (2-OCT) for primary closures solely on the trunk and extremities. METHODS: Patients undergoing surgery on the trunk and extremities with wounds ≥5 cm were eligible. Scar photos at 1 year were taken and assessed by 2 blinded Mohs surgeons using the Scar Cosmesis Assessment and Rating (SCAR) Scale. RESULTS: Fifty-eight patients were included in the study, with 70% of wounds on trunk and 29% on extremities. The mean SCAR scores did not differ significantly between the groups ( p = .78). Analysis of each scar characteristic did not differ significantly except for the presence of track marks in sutured wounds ( p = .04). 2-OCT performed significantly better on the chest compared to 5-PS ( p = .04) whereas no differences were seen on the arm or back. CONCLUSION: Aside for the presence of track marks in sutured wounds, the results show no significant difference in overall cosmesis between 5-PS and 2-OCT scars on the trunk and extremities.
2. Population-specific exposure risks from parabens and antimicrobials in cosmetics and personal care products: Insights from Korean usage patterns.
By combining measured chemical concentrations in 261 CPCPs with usage data from 2,042 Korean respondents, this study quantifies population-specific dermal doses of parabens and antimicrobials. Key contributors were skin care, sunscreens, and lotions; females and mothers had higher paraben and triclocarban exposure, and high-exposure scenarios increased doses 4–5-fold.
Impact: Provides realistic, population-specific exposure estimates directly tied to product categories, informing regulatory prioritization and risk mitigation for cosmetic and personal care ingredients.
Clinical Implications: Clinicians counseling pregnant women and high-use populations can recommend limiting high-contribution products (e.g., frequent use of skin care, sunscreens, lotions) and selecting lower-paraben formulations, while public health practitioners can target interventions by subgroup.
Key Findings
- Measured 13 parabens and 2 antimicrobials in 261 CPCPs; methylparaben and propylparaben were most prevalent.
- Estimated dermal paraben DEDs: males 11.4, females 25.8, mothers 25.1, infants 0.03 µg/kg/day; antimicrobial DEDs: males 0.20, females 0.28, mothers 0.98 µg/kg/day.
- Triclocarban frequently detected in rinse-off products; triclosan rarely detected, likely due to regulation.
- High-exposure scenarios raised DEDs by 4–5× versus general scenarios; skin care, sunscreens, body/hand lotions were major contributors.
Methodological Strengths
- Integration of product-level measured concentrations with large, population-specific usage data.
- Stratified exposure estimates across adults, teenagers, mothers, and infants with scenario analyses.
Limitations
- Cross-sectional exposure modeling without biomonitoring or health outcome linkage.
- Findings from Korea may not generalize to other regulatory or cultural settings; only two antimicrobials assessed.
Future Directions: Link exposure estimates to biomonitoring and endocrine outcomes, expand antimicrobial panels, and evaluate reformulation impacts on population exposures.
The use of cosmetics and personal care products (CPCPs) is a significant source of human exposure to endocrine disrupting chemicals (EDCs). However, few studies have investigated EDC exposure through CPCP use based on realistic exposure factors of diverse population groups. In this study, 13 parabens and two antimicrobial agents were measured in 261 CPCPs categorized as leave-on, rinse-off, and baby care products. Methylparaben and propylparaben were the most prevalent parabens. Triclocarban was frequently found in rinse-off products, while triclosan was rarely detected, likely due to regulatory measures. Population-specific exposure assessments were conducted using measured EDC concentrations and exposure factors derived from surveys of 1,001 adults, 322 teenagers, and 719 mother-infant pairs in Korea. Dermal exposure doses (DEDs) of parabens were estimated at 11.4, 25.8, 25.1 and 0.03 µg/kg/day for males, females, mothers, and infants, respectively. For antimicrobial agents, DEDs were 0.20, 0.28, and 0.98 µg/kg/day for males, females, and mothers, respectively. Females had higher DEDs of parabens than males in both adults and teenagers, and mothers had higher DEDs of triclocarban. These findings emphasized the need to consider population-specific characteristics in exposure assessments. High-exposure scenarios resulted in DEDs 4-5 times higher than general-exposure scenarios. Skin care products, sunscreens, body and hand lotions were major contributors to paraben exposure, highlighting the need for targeted management to mitigate exposure from these products. This study provides realistic exposure data that can serve as a valuable reference for managing CPCP ingredients, particularly parabens and antimicrobial agents.
3. Cepharantine prevents hypertrophic scarring by regulating the TGF-β/SMAD pathway.
In a rabbit ear model and complementary in vitro fibrosis assays, cepharanthine reduced scar hypertrophy, collagen content, and ECM production while downregulating TGF-β/SMAD signaling and fibroblast proliferation/migration. These findings support drug repurposing of cepharanthine as an anti-scarring agent.
Impact: Identifies a mechanistically targeted, repurposable small molecule for hypertrophic scar prevention, an area with unmet clinical need, and elucidates TGF-β/SMAD pathway modulation as the mechanism.
Clinical Implications: Cepharanthine merits early-phase clinical testing for hypertrophic scar prevention or treatment, particularly in high-risk wounds. Mechanistic data suggest potential synergy with other anti-fibrotic strategies targeting TGF-β signaling.
Key Findings
- In rabbit ear scars, cepharanthine significantly reduced scar hypertrophy index and collagen content and improved fibroblast arrangement.
- In vitro, cepharanthine downregulated key TGF-β/SMAD pathway proteins, decreased ECM protein expression, and suppressed fibroblast proliferation and migration.
- Findings support prevention of hypertrophic scarring via reduced ECM deposition through TGF-β/SMAD signaling modulation.
Methodological Strengths
- Convergent in vivo (rabbit ear) and in vitro fibrosis models with concordant outcomes.
- Mechanistic interrogation of TGF-β/SMAD signaling alongside phenotypic scar metrics.
Limitations
- Preclinical model without human clinical data; dosing, safety, and formulation parameters require clinical validation.
- Sample sizes and duration in animal studies are not detailed in the abstract, limiting appraisal of effect robustness.
Future Directions: Phase I/II trials assessing topical cepharanthine for scar prevention in high-risk incisions/burns; dose-ranging, safety, PK/PD, and biomarker-guided studies focusing on TGF-β/SMAD activity.
Hypertrophic scarring (HS) is a fibrotic skin disorder characterized by excessive deposition of extracellular matrix (ECM), leading to symptoms such as pain, itching, and skin contraction. HS can also result in restricted joint mobility and cosmetic deformities, imposing psychological and economic burdens on patients. Additionally, it increases wound care costs, and currently, no ideal treatment options exist. Therefore, HS is not only a clinical care issue but also a societal problem, with significant challenges related to its management and prevention. In this study, a custom-made cepharanthine ointment was applied to a rabbit ear scar model to investigate its effects on morphology, histology, and protein expression in HS. Additionally, the mechanism underlying the effect of cepharanthine on affected fibroblasts and the expression of ECM proteins was explored in vitro models of fibrosis. Animal experiments demonstrated that cepharanthine significantly reduced the tissue scar hypertrophy index and collagen content, improved the arrangement of fibroblasts, and inhibited ECM production. Cellular experiments indicated that cepharanthine effectively downregulated key proteins in the TGF-β/SMAD pathway, decreased ECM protein expression, and suppressed fibroblast proliferation and migration. Cepharanthine can prevent HS by reducing ECM deposition through the TGF-β/SMAD signalling pathway.